Technology | 2016.04.14
Gene-editing biotech Intellia files for $120 million IPO - STAT
| STAT | Gene- editing biotech Intellia files for $120 million IPO STAT Intellia Therapeutics, a biotech company that aims to use a revolutionary gene editing technology to treat rare diseases, is looking to raise as much as $120 million in an IPO to advance its early-stage science. The company, based in Cambridge, Mass ... Another Gene- Editing IPO Gene- Editing Company Intellia Discloses IPO Plan, Regeneron Pact One Thing that Could Stop the Rise of Gene Editing : Insurance Companies |
For more information, please visit
http://news.google.com/news/url?sa=t&fd=[...]/11/crispr-gene-edit-intellia/
